- Conditions
- Pregnancy Related
- Interventions
- Telehealth Visit
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1777–1800
of 9,381
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
- Drug
- Lead sponsor
- SkyePharma AG
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more
- Conditions
- Advanced Dupuytren's Disease
- Interventions
- collagenase clostridium histolyticum
- Biological
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Burbank, California + 10 more
- Conditions
- Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
- Interventions
- Idelalisib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Migraine Headache
- Interventions
- INP104
- Combination Product
- Lead sponsor
- Impel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 32 more
- Conditions
- Parkinson's Disease
- Interventions
- RO7046015, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cyproheptadine hydrochloride, megestrol acetate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 40
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
- Conditions
- Tyrosinemia I
- Interventions
- NTBC
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Adult Glioblastoma, Adult Gliosarcoma
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Cediranib Maleate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo Administration, Temozolomide
- Radiation · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 84 more
- Conditions
- Hypotension
- Interventions
- EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
- Device
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 11
- States / cities
- Stanford, California • Aurora, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Bintrafusp alfa
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more
- Conditions
- Hepatitis C
- Interventions
- Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Beverly Hills, California • Coronado, California + 37 more
- Conditions
- Hypertension
- Interventions
- Olmesartan medoxomil, Amlodipine
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study, Sorafenib Tosylate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 659
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 404 more
- Conditions
- Depressive Disorder
- Interventions
- orvepitant, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Orange, California + 23 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab, Matching Placebo to Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Encinitas, California • Encino, California + 41 more
- Conditions
- THROMBOLYSIS
- Interventions
- Tenecteplase, Placebo
- Biological · Other
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 94
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- Autism ALERT, Screening Intervention
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 12 Months to 54 Months
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- Cyclophosphamide, DRibble Vaccine, HPV Vaccinations, Imiquimod
- Drug · Biological
- Lead sponsor
- UbiVac
- Industry
- Eligibility
- Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Dementia With Lewy Bodies
- Interventions
- RVT-101 35 mg, RVT-101 70 mg, Placebo
- Drug
- Lead sponsor
- Axovant Sciences Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 105
- States / cities
- Fremont, California • Los Angeles, California • San Francisco, California + 37 more
- Conditions
- Coronary Artery Disease
- Interventions
- 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
- Drug · Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,009 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
- Conditions
- Myositis
- Interventions
- Nipocalimab, Placebo, Glucocorticoids
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cemiplimab, Cisplatin, Computed Tomography, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Salvage Surgery
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 115
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 85 more